Summary:
Double-Blind, Single and Multiple Dose Study to Determine Pharmacodynamic Markers, Pharmacokinetic Parameters, and Safety of ALTO-203 in Patients with Major Depressive Disorder
Qualified Participants Must:
Be aged 25 to 64 years old
have a diagnosis of MDD
have presence of anhedonia symptoms
not be taking any antidepressant medication
Qualified Participants May Receive:
Study-related care
Investigational Treatment or Placebo
Compensation up to $1850